Repurposed AstraZeneca PLC drugs will be evaluated in three of the nine research projects to be funded by the National Institutes of Health’s National Center for Advancing Translational Sciences in its pilot program to identify new uses for existing compounds.
Announced June 18, the nine projects will be funded with a total of $12.7 million and cover eight disease areas....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?